Annual EBIT
-$14.05 M
-$2.34 M-20.01%
December 31, 2022
Summary
- As of February 8, 2025, NAVB annual earnings before interest & taxes is -$14.05 million, with the most recent change of -$2.34 million (-20.01%) on December 31, 2022.
- During the last 3 years, NAVB annual EBIT has fallen by -$3.09 million (-28.17%).
- NAVB annual EBIT is now -953.74% below its all-time high of $1.65 million, reached on December 31, 2000.
Performance
NAVB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$2.13 M
+$296.40 K+12.21%
September 30, 2023
Summary
- As of February 8, 2025, NAVB quarterly earnings before interest & taxes is -$2.13 million, with the most recent change of +$296.40 thousand (+12.21%) on September 30, 2023.
- Over the past year, NAVB quarterly EBIT has increased by +$296.40 thousand (+12.21%).
- NAVB quarterly EBIT is now -403.86% below its all-time high of $701.40 thousand, reached on December 31, 2000.
Performance
NAVB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$9.00 M
+$2.82 M+23.86%
September 30, 2023
Summary
- As of February 8, 2025, NAVB TTM earnings before interest & taxes is -$9.00 million, with the most recent change of +$2.82 million (+23.86%) on September 30, 2023.
- Over the past year, NAVB TTM EBIT has increased by +$2.82 million (+23.86%).
- NAVB TTM EBIT is now -620.83% below its all-time high of $1.73 million, reached on March 31, 2001.
Performance
NAVB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
NAVB EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.0% | +12.2% | +23.9% |
| 3 y3 years | -28.2% | +12.2% | +23.9% |
| 5 y5 years | -1.3% | +12.2% | +23.9% |
NAVB EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.0% | at low | -75.7% | +57.0% | at high | +36.4% |
| 5 y | 5-year | -31.2% | at low | -75.7% | +57.0% | at high | +36.4% |
| alltime | all time | -953.7% | +74.8% | -403.9% | +94.0% | -620.8% | +77.5% |
Navidea Biopharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$2.13 M(-12.2%) | -$9.00 M(-23.9%) |
| Jun 2023 | - | -$2.43 M(+100.1%) | -$11.82 M(-4.0%) |
| Mar 2023 | - | -$1.21 M(-62.4%) | -$12.31 M(-12.6%) |
| Dec 2022 | -$14.05 M(+20.0%) | -$3.23 M(-34.8%) | -$14.08 M(-0.4%) |
| Sep 2022 | - | -$4.95 M(+69.4%) | -$14.14 M(+21.8%) |
| Jun 2022 | - | -$2.92 M(-2.0%) | -$11.62 M(+2.2%) |
| Mar 2022 | - | -$2.98 M(-9.2%) | -$11.36 M(+0.2%) |
| Dec 2021 | -$11.71 M(+9.3%) | -$3.29 M(+35.7%) | -$11.34 M(+4.5%) |
| Sep 2021 | - | -$2.42 M(-9.3%) | -$10.86 M(-4.2%) |
| Jun 2021 | - | -$2.67 M(-9.9%) | -$11.33 M(+3.0%) |
| Mar 2021 | - | -$2.96 M(+5.8%) | -$11.00 M(+2.7%) |
| Dec 2020 | -$10.71 M(-2.3%) | -$2.80 M(-3.4%) | -$10.71 M(+0.3%) |
| Sep 2020 | - | -$2.90 M(+23.8%) | -$10.68 M(-1.7%) |
| Jun 2020 | - | -$2.34 M(-12.4%) | -$10.87 M(-3.0%) |
| Mar 2020 | - | -$2.67 M(-3.6%) | -$11.20 M(+2.2%) |
| Dec 2019 | -$10.96 M(+1.1%) | -$2.77 M(-10.1%) | -$10.96 M(+5.5%) |
| Sep 2019 | - | -$3.08 M(+15.4%) | -$10.39 M(-5.8%) |
| Jun 2019 | - | -$2.67 M(+9.8%) | -$11.03 M(+2.3%) |
| Mar 2019 | - | -$2.43 M(+10.5%) | -$10.78 M(-0.6%) |
| Dec 2018 | -$10.85 M(-21.8%) | -$2.20 M(-40.8%) | -$10.85 M(-10.8%) |
| Sep 2018 | - | -$3.72 M(+53.4%) | -$12.17 M(+12.3%) |
| Jun 2018 | - | -$2.43 M(-3.0%) | -$10.83 M(-18.1%) |
| Mar 2018 | - | -$2.50 M(-29.0%) | -$13.23 M(-4.7%) |
| Dec 2017 | -$13.88 M(+36.7%) | -$3.52 M(+47.5%) | -$13.88 M(+2.1%) |
| Sep 2017 | - | -$2.39 M(-50.5%) | -$13.60 M(+12.2%) |
| Jun 2017 | - | -$4.82 M(+53.3%) | -$12.12 M(+27.1%) |
| Mar 2017 | - | -$3.15 M(-2.8%) | -$9.54 M(-6.0%) |
| Dec 2016 | -$10.15 M(-45.0%) | -$3.24 M(+256.1%) | -$10.15 M(+8.0%) |
| Sep 2016 | - | -$909.80 K(-59.4%) | -$9.40 M(-26.6%) |
| Jun 2016 | - | -$2.24 M(-40.4%) | -$12.81 M(-10.9%) |
| Mar 2016 | - | -$3.76 M(+50.9%) | -$14.38 M(-22.0%) |
| Dec 2015 | -$18.44 M(-33.3%) | -$2.49 M(-42.4%) | -$18.44 M(-9.7%) |
| Sep 2015 | - | -$4.32 M(+13.4%) | -$20.43 M(-4.8%) |
| Jun 2015 | - | -$3.81 M(-51.2%) | -$21.47 M(-20.1%) |
| Mar 2015 | - | -$7.82 M(+74.6%) | -$26.87 M(-2.8%) |
| Dec 2014 | -$27.63 M(-28.1%) | -$4.48 M(-16.5%) | -$27.63 M(-19.8%) |
| Sep 2014 | - | -$5.36 M(-41.8%) | -$34.45 M(-12.6%) |
| Jun 2014 | - | -$9.22 M(+7.4%) | -$39.42 M(-1.5%) |
| Mar 2014 | - | -$8.58 M(-24.0%) | -$40.04 M(+4.2%) |
| Dec 2013 | -$38.44 M(+37.3%) | -$11.30 M(+9.3%) | -$38.44 M(+12.6%) |
| Sep 2013 | - | -$10.33 M(+5.0%) | -$34.14 M(+4.7%) |
| Jun 2013 | - | -$9.84 M(+40.9%) | -$32.59 M(+15.3%) |
| Mar 2013 | - | -$6.98 M(-0.3%) | -$28.27 M(+1.0%) |
| Dec 2012 | -$27.99 M(+11.8%) | -$7.00 M(-20.3%) | -$27.99 M(-6.8%) |
| Sep 2012 | - | -$8.78 M(+59.3%) | -$30.02 M(+8.4%) |
| Jun 2012 | - | -$5.51 M(-17.7%) | -$27.70 M(+7.4%) |
| Mar 2012 | - | -$6.70 M(-25.8%) | -$25.78 M(+3.0%) |
| Dec 2011 | -$25.03 M(-55.0%) | -$9.03 M(+39.8%) | -$25.03 M(+27.0%) |
| Sep 2011 | - | -$6.46 M(+79.7%) | -$19.72 M(+16.2%) |
| Jun 2011 | - | -$3.60 M(-39.6%) | -$16.96 M(+18.6%) |
| Mar 2011 | - | -$5.95 M(+60.4%) | -$14.30 M(+41.8%) |
| Dec 2010 | -$55.69 M(+2951.6%) | -$3.71 M(+0.2%) | -$10.08 M(+48.5%) |
| Sep 2010 | - | -$3.70 M(+298.8%) | -$6.79 M(+99.2%) |
| Jun 2010 | - | -$928.70 K(-46.5%) | -$3.41 M(+1.5%) |
| Mar 2010 | - | -$1.74 M(+313.1%) | -$3.36 M(+84.0%) |
| Dec 2009 | -$1.82 M(-27.2%) | -$420.20 K(+29.7%) | -$1.82 M(+12.3%) |
| Sep 2009 | - | -$324.00 K(-63.1%) | -$1.63 M(-42.3%) |
| Jun 2009 | - | -$877.30 K(+331.3%) | -$2.82 M(+17.7%) |
| Mar 2009 | - | -$203.40 K(-8.0%) | -$2.39 M(-4.5%) |
| Dec 2008 | -$2.51 M | -$221.00 K(-85.4%) | -$2.51 M(-93.4%) |
| Sep 2008 | - | -$1.52 M(+233.8%) | -$38.09 M(+3.9%) |
| Jun 2008 | - | -$454.20 K(+43.6%) | -$36.66 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$316.30 K(-99.1%) | -$36.92 M(-1.0%) |
| Dec 2007 | -$37.29 M(+977.7%) | -$35.80 M(>+9900.0%) | -$37.29 M(+1445.2%) |
| Sep 2007 | - | -$90.00 K(-87.3%) | -$2.41 M(-34.1%) |
| Jun 2007 | - | -$708.00 K(+2.2%) | -$3.66 M(+4.1%) |
| Mar 2007 | - | -$692.60 K(-24.9%) | -$3.52 M(+1.6%) |
| Dec 2006 | -$3.46 M(-5.0%) | -$922.80 K(-31.1%) | -$3.46 M(-2.3%) |
| Sep 2006 | - | -$1.34 M(+137.7%) | -$3.54 M(+10.8%) |
| Jun 2006 | - | -$563.20 K(-11.4%) | -$3.20 M(-13.7%) |
| Mar 2006 | - | -$636.00 K(-36.7%) | -$3.71 M(+1.8%) |
| Dec 2005 | -$3.64 M(+82.3%) | -$1.01 M(+1.1%) | -$3.64 M(+3.6%) |
| Sep 2005 | - | -$994.30 K(-7.3%) | -$3.52 M(+29.1%) |
| Jun 2005 | - | -$1.07 M(+87.5%) | -$2.72 M(+32.2%) |
| Mar 2005 | - | -$572.00 K(-34.8%) | -$2.06 M(+3.1%) |
| Dec 2004 | -$2.00 M(+24.1%) | -$877.50 K(+334.4%) | -$2.00 M(+22.0%) |
| Sep 2004 | - | -$202.00 K(-50.6%) | -$1.64 M(-18.6%) |
| Jun 2004 | - | -$408.60 K(-20.0%) | -$2.01 M(+22.0%) |
| Mar 2004 | - | -$511.00 K(-1.2%) | -$1.65 M(+2.4%) |
| Dec 2003 | -$1.61 M(-46.7%) | -$517.20 K(-10.2%) | -$1.61 M(+24.9%) |
| Sep 2003 | - | -$575.70 K(+1170.9%) | -$1.29 M(-28.7%) |
| Jun 2003 | - | -$45.30 K(-90.4%) | -$1.81 M(-31.7%) |
| Mar 2003 | - | -$472.90 K(+141.5%) | -$2.65 M(-12.4%) |
| Dec 2002 | -$3.02 M(-667.4%) | -$195.80 K(-82.1%) | -$3.02 M(+16.2%) |
| Sep 2002 | - | -$1.09 M(+23.8%) | -$2.60 M(+89.5%) |
| Jun 2002 | - | -$883.80 K(+4.2%) | -$1.37 M(+301.9%) |
| Mar 2002 | - | -$847.80 K(-474.5%) | -$341.30 K(-164.0%) |
| Dec 2001 | $532.50 K(-67.6%) | $226.40 K(+69.7%) | $533.20 K(-47.1%) |
| Sep 2001 | - | $133.40 K(-9.1%) | $1.01 M(-23.0%) |
| Jun 2001 | - | $146.70 K(+449.4%) | $1.31 M(-24.2%) |
| Mar 2001 | - | $26.70 K(-96.2%) | $1.73 M(+5.0%) |
| Dec 2000 | $1.65 M(-135.9%) | $701.40 K(+61.5%) | $1.65 M(+74.3%) |
| Sep 2000 | - | $434.30 K(-23.2%) | $944.50 K(+85.1%) |
| Jun 2000 | - | $565.30 K(-1126.0%) | $510.20 K(-144.2%) |
| Mar 2000 | - | -$55.10 K(-95.0%) | -$1.16 M(-93.7%) |
| Dec 1999 | -$4.58 M(-83.9%) | - | - |
| Jun 1999 | - | -$1.10 M(-21.4%) | -$18.27 M(-16.1%) |
| Mar 1999 | - | -$1.40 M(-88.3%) | -$21.77 M(-21.3%) |
| Dec 1998 | -$28.47 M(+4.4%) | -$11.97 M(+215.0%) | -$27.67 M(+14.5%) |
| Sep 1998 | - | -$3.80 M(-17.4%) | -$24.16 M(-6.9%) |
| Jun 1998 | - | -$4.60 M(-37.0%) | -$25.96 M(-10.7%) |
| Mar 1998 | - | -$7.30 M(-13.8%) | -$29.06 M(+7.0%) |
| Dec 1997 | -$27.26 M(+16.5%) | -$8.46 M(+51.2%) | -$27.16 M(+2.9%) |
| Sep 1997 | - | -$5.60 M(-27.3%) | -$26.40 M(-4.7%) |
| Jun 1997 | - | -$7.70 M(+42.6%) | -$27.70 M(+9.1%) |
| Mar 1997 | - | -$5.40 M(-29.9%) | -$25.40 M(+5.8%) |
| Dec 1996 | -$23.40 M(+105.3%) | -$7.70 M(+11.6%) | -$24.00 M(+22.4%) |
| Sep 1996 | - | -$6.90 M(+27.8%) | -$19.60 M(+25.6%) |
| Jun 1996 | - | -$5.40 M(+35.0%) | -$15.60 M(+20.9%) |
| Mar 1996 | - | -$4.00 M(+21.2%) | -$12.90 M(+9.3%) |
| Dec 1995 | -$11.40 M(-3.4%) | -$3.30 M(+13.8%) | -$11.80 M(-5.6%) |
| Sep 1995 | - | -$2.90 M(+7.4%) | -$12.50 M(0.0%) |
| Jun 1995 | - | -$2.70 M(-6.9%) | -$12.50 M(+5.0%) |
| Mar 1995 | - | -$2.90 M(-27.5%) | -$11.90 M(+2.6%) |
| Dec 1994 | -$11.80 M(+43.9%) | -$4.00 M(+37.9%) | -$11.60 M(+14.9%) |
| Sep 1994 | - | -$2.90 M(+38.1%) | -$10.10 M(+7.4%) |
| Jun 1994 | - | -$2.10 M(-19.2%) | -$9.40 M(+1.1%) |
| Mar 1994 | - | -$2.60 M(+4.0%) | -$9.30 M(+16.3%) |
| Dec 1993 | -$8.20 M(+173.3%) | -$2.50 M(+13.6%) | -$8.00 M(+19.4%) |
| Sep 1993 | - | -$2.20 M(+10.0%) | -$6.70 M(+26.4%) |
| Jun 1993 | - | -$2.00 M(+53.8%) | -$5.30 M(+60.6%) |
| Mar 1993 | - | -$1.30 M(+8.3%) | -$3.30 M(+65.0%) |
| Dec 1992 | -$3.00 M | -$1.20 M(+50.0%) | -$2.00 M(+150.0%) |
| Sep 1992 | - | -$800.00 K | -$800.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual EBIT year-on-year change?
- What is Navidea Biopharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly EBIT year-on-year change?
- What is Navidea Biopharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals TTM EBIT year-on-year change?
What is Navidea Biopharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of NAVB is -$14.05 M
What is the all time high annual EBIT for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual earnings before interest & taxes is $1.65 M
What is Navidea Biopharmaceuticals annual EBIT year-on-year change?
Over the past year, NAVB annual earnings before interest & taxes has changed by -$2.34 M (-20.01%)
What is Navidea Biopharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of NAVB is -$2.13 M
What is the all time high quarterly EBIT for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly earnings before interest & taxes is $701.40 K
What is Navidea Biopharmaceuticals quarterly EBIT year-on-year change?
Over the past year, NAVB quarterly earnings before interest & taxes has changed by +$296.40 K (+12.21%)
What is Navidea Biopharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of NAVB is -$9.00 M
What is the all time high TTM EBIT for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high TTM earnings before interest & taxes is $1.73 M
What is Navidea Biopharmaceuticals TTM EBIT year-on-year change?
Over the past year, NAVB TTM earnings before interest & taxes has changed by +$2.82 M (+23.86%)